Autopsy report · NCT02649751

Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“The centers have no longer patients. In September 2018, set up of a competitive international study.”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 2 years 5 months before it stopped.
49 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: University Hospital, Brest
Sponsor type: University, hospital or other
Conditions: Cystic Fibrosis
Interventions: Roscovitine; Placebo
Participants: 49
Sites: 11
Countries: France

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.